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Background: Members of the urokinase-type plasminogen activator (uPA) system including uPA, its receptor uPAR
and the plasminogen activator inhibitor 1 (PAI-1) play an important role in tumour invasion and progression in a
variety of tumour types. Since the majority of clear cell renal cell carcinoma (ccRCC) shows distant metastasis at
time of diagnosis or later, the interplay of uPA, uPAR and PAI-1 might be of importance in this process determining
the patients’ outcome.
Methods: Corresponding pairs of malignant and non-malignant renal tissue specimens were obtained from 112
ccRCC patients without distant metastasis who underwent tumour nephrectomy. Tissue extracts prepared from
fresh-frozen tissue samples by detergent extraction were used for the determination of antigen levels of uPA,
uPAR and PAI-1 by ELISA. Antigen levels were normalised to protein concentrations and expressed as ng per mg
of total protein.
Results: Antigen levels of uPA, uPAR, and PAI-1 correlated with each other in the malignant tissue specimens
(rs=0.51-0.65; all P<0.001). Antigen levels of uPA system components were significantly higher in tissue extracts
of non-organ confined tumours (pT3+4) compared to organ-confined tumours (pT1+2; all P<0.05). Significantly
elevated levels of uPAR and PAI-1 were also observed in high grade ccRCC. When using median antigen levels as
cut-off points, all three uPA system factors were significant predictors for disease-specific survival (DSS) in univariate
Cox’s regression analyses. High levels of uPA and uPAR remained independent predictors for DSS with HR=2.86
(95% CI 1.07-7.67, P=0.037) and HR=4.70 (95% CI 1.51-14.6, P=0.008), respectively, in multivariate Cox’s regression
analyses. A combination of high antigen levels of uPA and/or uPAR further improved the prediction of DSS in
multivariate analysis (HR=14.5, 95% CI 1.88-111.1, P=0.010). Moreover, high uPA and/or uPAR levels defined a patient
subgroup of high risk for tumour-related death in ccRCC patients with organ-confined disease (pT1+2) (HR=9.83,
95% CI 1.21-79.6, P=0.032).
Conclusions: High levels of uPA and uPAR in tumour tissue extracts are associated with a significantly shorter DSS
of ccRCC patients without distant metastases.
Keywords: PAI-1, Prognostic biomarker, Renal cell carcinoma, uPA, uPAR, uPA system* Correspondence: susanne.fuessel@uniklinikum-dresden.de
†Equal contributors
1Department of Urology, Technische Universität Dresden, Fetscherstrasse 74,
01307 Dresden, Germany
Full list of author information is available at the end of the article
© 2014 Fuessel et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Fuessel et al. BMC Cancer 2014, 14:974 Page 2 of 12
http://www.biomedcentral.com/1471-2407/14/974Background
Renal cell carcinoma (RCC), comprising 3-4% of all ma-
lignant neoplasms, is the third most common urological
tumour entity and the 13th most common malignancy
worldwide [1,2]. Clear cell RCC (ccRCC) is the most
common and the most aggressive subtype of this disease
[3]. About one third of the patients already present dis-
tant metastases at the time of diagnosis, whereas nearly
another third develops metastases during the course of
the disease [1,4]. Although the application of target-
directed therapeutics improved the outcome of pa-
tients with metastatic ccRCC their prognosis remains
unfavourable [5].
Since the disease progression of RCC is still not suffi-
ciently predictable by clinical and histopathological pa-
rameters, there is an urgent need for additional powerful
biological prognostic factors that may help to refine indi-
vidual risk stratification of RCC patients. A reliable pre-
diction of outcome after nephrectomy by such markers
would be valuable to tailor individualised follow-up
schedules and to provide adjuvant therapies to patients
at high risk of relapse [6]. Several clinicopathological pa-
rameters and molecular biomarkers or their combination
have been described to be prognostically useful for RCC
[7-9]. Nevertheless, further research and validation of
these molecular markers for diagnostic and prognostic
purposes in RCC patients are still necessary.
The urokinase-type plasminogen activator (uPA) sys-
tem consisting mainly of uPA, the uPA receptor (uPAR)
and the plasminogen activator inhibitor-1 (PAI-1) has
been shown to play a key role in physiological and
pathological pathways including carcinogenesis [10-12].
In addition to extracellular proteolysis, uPA in concert
with uPAR and/or PAI-1 induces cell signaling pathways
that affect multiple steps of cancer progression such as
angiogenesis, cell growth, cell adhesion and migration,
chemotaxis and cell survival [10,11,13,14].
High expression levels of uPA and/or PAI-1 in tumour
tissue extracts have been found to be strong predictors
of poor prognosis in patients afflicted with different
types of solid malignant tumours [15,16]. High uPAR
levels are also associated with poor prognosis in a var-
iety of cancer types, however, the prognostic impact of
uPAR expression is not as pronounced as that of uPA
and PAI-1 [17,18].
To date, only few studies exist that characterise the
role of uPA system members in RCC and analyse their
association with clinicopathological parameters and their
impact on the outcome of RCC patients. High uPA,
uPAR and/or PAI-1 protein expression in tumour tissue
of RCC patients, detected by immunohistochemistry,
was significantly associated with higher tumour stage, me-
tastasis and poor disease-specific survival in a cohort of 106
RCC patients [19]. Furthermore, significant associationswere observed between high immunoexpression of PAI-1
in tumour tissue of ccRCC patients and older age, advanced
tumour stage, high nuclear grade, and disease progression
[20,21]. In survival analyses, strong PAI-1 immunostaining
was associated with a shorter disease-free survival of ccRCC
patients [20]. Furthermore, high PAI-1 immunoexpression
was identified as an independent predictor of cancer-
specific survival in a cohort of 172 ccRCC patients [21].
Increased uPA, uPAR and/or PAI-1 antigen levels in
tumour tissue extracts, as determined by ELISA, were
found to be related to high tumour grade of RCC
[22,23]. Hofmann et al. [24,25], who also measured
antigen levels of uPA, uPAR and PAI-1 in renal tissue
extracts from RCC patients by ELISA, revealed all
three factors as strong and independent predictors for
early relapse.
Thus, the above-mentioned studies point to a rather
strong clinical relevance of the members of the uPA-
system in RCC, however, with some important limita-
tions. Most of these data were obtained using tissue
samples originating from different RCC subtypes, incon-
sistent cohort sizes, optimised cut-off points, the use of
non-detergent tissue extracts or the three factors were
not analysed in parallel. Therefore, in the present study,
uPA, uPAR and PAI-1 antigen levels were determined in
detergent tissue extracts derived from corresponding
malignant and non-malignant renal tissues of 112 RCC
patients of the clear-cell subtype without clinically de-
tectable distant metastases at the time of diagnosis by
ELISA. The antigen concentrations of uPA system com-
ponents in tissue extracts were analysed for correlations
between these factors themselves and for potential
associations with clinicopathological parameters. In
addition, we assessed the prognostic power of these
markers for the prediction of disease-specific survival
(DSS) and overall survival (OS) to validate their use-




In total, 112 patients with ccRCC were included in this
retrospective study that was approved by the institu-
tional review boards of the Technische Universität
Dresden and the Martin Luther University Halle-
Wittenberg. Written informed consent was obtained
from all patients. Patients were treated by partial or
radical tumour nephrectomy between 1994 and 2001
at either the Department of Urology of the Technische
Universität Dresden or the Department of Urology of the
Martin Luther University Halle-Wittenberg. Tumours were
restaged according to the UICC-classification 2010 [26];
tumour grading was performed according to Fuhrman
et al. [27]. The patient cohort consisted of 65 men (58%)
Table 1 Clinical and histopathological characteristics of
the ccRCC patients























died of ccRCC 21 (18.8)
Death of any cause (OS)
alive 74 (66.1)
died of any cause 38 (33.9)
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38–88 years). Organ-confined tumours (pT1+pT2) were
found in 87 patients (78%), and non-organ confined tu-
mours (pT3+pT4) in 25 patients (22%). 68 patients (61%)
had low grade tumours (G1+G2), whereas 44 patients
(39%) displayed high grade tumours (G3+G4). None of
the patients included in the study showed clinically
detectable distant metastasis at the time of diagnosis, but
6 patients (5%) had tumour-positive lymph nodes (pN1).
Furthermore, patients with distant metastases detected
within six months after primary surgery were excluded
from the study.
Follow-up data were collected with regard to death of
patients and cause of death. Median follow up for all pa-
tients comprised 101 months (range 9–188 months)
with 38 deaths of any cause (33.9%; median survival 61.5
months) in the analysis of OS and with 21 patients
(18.8%; median survival 32.0 months) who died of
ccRCC in the analysis of DSS. All clinical and histo-
pathological characteristics of the ccRCC patients are
given in Table 1.
Determination of tissue antigen levels by ELISA
Matched pairs of malignant and non-malignant renal tis-
sue specimens obtained directly after surgery were snap-
frozen and stored in liquid nitrogen until further use.
Detergent tissue extracts were prepared from frozen
renal tissue specimens as previously described [28,29].
The use of detergent-containing extraction buffer was
recommended by the manufacturer, since it allows the
reliable extraction of uPA, PAI-1 and the membrane-
bound uPA receptor and the parallel determination of
all three factors in one tissue extract [28,30]. Briefly,
after solubilisation of membrane-bound proteins using
Tris-buffer containing the non-ionic detergent Triton X-
100 (1%), cell debris was separated by centrifugation and
the supernatant was stored at -80°C until use. The uPA,
uPAR and PAI-1 antigen content in tissue extracts of
ccRCC patients was determined applying commercially
available ELISA kits (IMUBIND uPA ELISA # 894, IMU-
BIND uPAR ELISA # 893 and IMUBIND Tissue PAI-1
ELISA # 821; American Diagnostica/Sekisui Diagnostics,
Stamford, CT, USA) according to the manufacturer’s in-
structions. IMUBIND ELISA tests for uPA and PAI-1 have
previously been extensively validated in quality assessment
trials by an EORTC study group [31]. The protein content
of tumour tissue extracts was determined using the BCA
protein assay (Sigma, Deisenhofen, Germany). Antigen con-
centrations in tissue extracts were expressed as ng analyte
per mg of total protein.
Statistical analyses
The distribution of protein levels of uPA, uPAR and
PAI-1 in malignant and non-malignant tissue specimensis presented by boxplots. The Wilcoxon test was used to
test for significant differences in antigen levels between
both sample groups.
Correlations between continuous variables of the three
uPA system components were assessed by Spearman's
rank correlation coefficients (rs). The relationship of anti-
gen levels with clinicopathological parameters was evalu-
ated using the non-parametric Mann–Whitney test. DSS
and OS of ccRCC patients were used as follow-up end
points for survival analyses. The median levels were set as
cut points to separate ccRCC patients in groups with low
or high marker expression. For statistical analyses of the
association between expression of uPA system compo-
nents and patients’ prognosis univariate and multivariate
Cox’s proportional hazard regression models were used to
calculate the hazard ratio (HR) and its 95% confidence
interval (CI) in the analysis of OS and DSS. The multivari-
ate Cox’s regression models were adjusted to known clin-
ical prognostic factors in ccRCC patients such as gender,
Figure 1 Protein levels in matched pairs of malignant and
non-malignant renal tissue specimens. Distribution of protein
levels of A) uPA, B) uPAR and C) PAI-1 in malignant (Tu) and
non-malignant (Tf) renal tissues from 112 ccRCC patients assessed
by ELISA is presented by boxplots. The boxes represent the 25th –
75th percentiles, the whiskers indicate the 10th and 90th percentiles.
The median values are depicted as solid lines within the boxes. The
Wilcoxon test was used to test for significant differences in antigen
levels between Tu and Tf.
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generated using Kaplan-Meier analysis applying the log-
rank test to look for differences in survival. All calcula-
tions were performed using the StatView 5.0 statistical
package (SAS Institute, Cary, NC, USA). P-values < 0.05
were considered as statistically significant.
Results
Comparison of uPA system component levels in
corresponding malignant and non-malignant tissue
specimens of ccRCC patients
The median normalised antigen levels (ng/mg protein)
of uPA, uPAR, and PAI-1 were 0.41 (range 0.03 - 7.44),
0.51 (range 0.16 - 8.31), and 10.3 (range 1.28 – 3738.3),
respectively, in the ccRCC tissues. In tissue extracts of
the adjacent non-malignant tissue median antigen levels
of 0.61 (range 0.09 - 4.99), 0.52 (range 0.10 - 6.17), and
3.13 (range 1.17 – 34.5) were determined for uPA,
uPAR, and PAI-1, respectively (Figure 1).
Significantly reduced antigen levels of uPA were ob-
served in the tumour tissue specimens compared to the
corresponding non-malignant tissues (P = 0.002),
whereas PAI-1 antigen levels were significantly increased
in tumour tissue specimens (P < 0.001). In contrast, no
significant differences in protein levels between malig-
nant and non-malignant tissue samples were observed
for uPAR (P = 0.306). The distribution of the uPA,
uPAR, and PAI-1 antigen levels in tissue extracts of the
corresponding tissue pairs is shown in Figure 1.
Antigen levels of the uPA system components in
tumour tissue specimens showed a moderate, significant
correlation amongst each other. Spearman’s correlation
coefficients of rs = 0.51 (P < 0.001) were calculated for
the association between uPA and uPAR, of rs = 0.54
(P < 0.001) for uPA with PAI-1 and of rs = 0.65 (P < 0.001)
for uPAR with PAI-1. Conversely, only a low correlation
(rs < 0.28) was observed between uPA system component
levels in non-malignant tissue specimens.
Association of uPA system component levels in tumour
tissue with clinicopathological parameters of ccRCC
patients
Associations of uPA, uPAR and PAI-1 antigen levels in
tumour tissue extracts with relevant clinicopathological
factors are summarised in Table 2. Levels of uPA in
tumour tissue samples differed significantly between
male and female patients (P = 0.002), whereas the associ-
ation of uPAR and PAI-1 with gender was not significant.
Significantly higher levels of uPAR, but not of uPA and
PAI-1, were observed in patients at higher age (older than
the median of 64 years) compared to younger patients (P =
0.029). Furthermore, antigen levels of all three uPA system
factors were significantly elevated in tumour tissue from
non-organ confined tumours (pT3+4) compared to organ-confined tumours (pT1+2; all P < 0.05). High grade tu-
mours (G3+4) displayed significantly increased levels
of uPAR (P = 0.008) and PAI-1 (P = 0.011) in compari-
son to low grade tumours (G1+2). However, uPA
levels in tumour tissue extracts were not related to
tumour grade (Table 2).
Table 2 Protein levels of uPA system components in tumour tissue specimens in relation to clinicopathological
parameters of the ccRCC patients
Clinicopathological parameters No. patients uPAa uPARa PAI-1a
Total 112 0.41 (0.4) 0.51 (0.7) 10.31 (20.7)
Genderb P = 0.002 P = 0.065 P = 0.056
male 65 0.47 (0.6) 0.60 (0.7) 12.58 (29.1)
female 47 0.30 (0.3) 0.42 (0.5) 7.18 (13.9)
Age (years)b P = 0.117 P = 0.029 P = 0.242
≤64 57 0.36 (0.3) 0.43 (0.4) 8.98 (13.4)
>64 55 0.46 (0.7) 0.63 (0.7) 11.74 (54.7)
Tumour stageb P = 0.003 P = 0.021 P = 0.010
pT1+2 87 0.36 (0.3) 0.47 (0.5) 8.33 (14.0)
pT3+4 25 0.63 (0.9) 0.81 (1.4) 18.05 (62.3)
Tumour gradeb P = 0.122 P = 0.008 P = 0.011
G1+2 68 0.40 (0.3) 0.43 (0.5) 7.83 (12.8)
G3+4 44 0.43 (0.9) 0.68 (1.1) 14.57 (62.9)
Disease-specific survivalb P = 0.220 P = 0.002 P = 0.007
alive 91 0.37 (0.4) 0.46 (0.5) 7.91 (14.4)
died of ccRCC 21 0.50 (0.7) 0.94 (0.8) 16.08 (65.0)
Overall survivalb P = 0.568 P = 0.013 P = 0.037
alive 74 0.38 (0.4) 0.45 (0.4) 7.59 (17.7)
died of any cause 38 0.46 (0.5) 0.69 (0.7) 12.57 (57.1)
aMedian values (interquartile range), ng analyte/mg protein; bMann-Whitney test.
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of ccRCC patients
For statistical analyses of the impact of uPA system
components on patients’ survival, the median protein ex-
pression levels of uPA, uPAR, and PAI-1 were used as
cut-off points to classify the ccRCC patients into groups
with low or high antigen levels in tumour tissue extracts.
In univariate Cox’s regression analyses, high antigen
levels of all three uPA system components in tumour tis-
sue were significantly associated with both shorter DSS
and OS of ccRCC patients, except for uPA, for which an
association of high antigen levels was observed with OS
only (Additional file 1: Table S1). These findings were con-
firmed by the log-rank test which also revealed signifi-
cantly shorter DSS of patients with high levels of uPA
system components (P = 0.013, P = 0.001, and P = 0.022
for uPA, uPAR, and PAI-1, respectively) as exemplarily
visualised by the respective survival curves (Figure 2).
Furthermore, the relevant clinicopathological parame-
ters age, tumour stage and tumour grade were univariate
predictors for DSS. However, in univariate analysis of OS
only age and tumour grade reached statistical significance,
whereas gender did not affect outcome of ccRCC patients
in neither DSS nor OS (Additional file 1: Table S1).
The independent relationship of uPA system compo-
nents with DSS and OS of ccRCC patients was evaluated
by multivariate Cox’s regression analyses by adding thesefactors separately to a base model consisting of clinico-
pathological parameters including gender, age, tumour
stage and tumour grade. Strikingly, uPA and uPAR anti-
gen levels in tumour tissue extracts were significantly
associated with shorter DSS, whereas none of the clini-
copathological parameters showed a significant predict-
ive value towards DSS (Table 3). For ccRCC patients
with either high uPA (HR = 2.86; 95% CI 1.07-7.67; P =
0.037) or uPAR antigen levels (HR = 4.70; 95% CI 1.51-
14.6; P = 0.008) we observed a significantly increased
risk of cancer-related death compared with those pa-
tients who displayed low uPA or uPAR antigen levels in
ccRCC tissue (Table 3). PAI-1 antigen levels were associ-
ated with DSS only by trend in multivariate analysis
(HR = 2.59; 95% CI 0.95-7.08; P = 0.064). When adding
all three factors simultaneously to the basic model, only
uPAR remained an independent prognostic factor for
DSS with HR = 3.54 (95% CI 1.02-12.2, P = 0.046). In
contrast, uPA system members did not emerge as inde-
pendent prognosticators for OS (Table 3). Among the
clinicopathological parameters only age displayed an in-
dependent prognostic value for OS (Table 3).
In addition, we performed statistical analyses in the
subgroup of ccRCC patients with organ-confined tu-
mours (pT1+2; n = 87). Here, the clinicopathological
variables were not significantly related to the patients’
survival, except for age, which was a significant predictor
Figure 2 Disease-specific survival of the ccRCC patients in
relation to the uPA system components. Kaplan-Meier curves
show the dependence of disease-specific survival (DSS) on the
protein levels of A) uPA, B) uPAR and C) PAI-1. Differences in DSS
between patients with low and high levels of the uPA system
components were assessed using the log-rank test.
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1: Tables S2 and S3). Likewise, no significant associa-
tions were observed between uPA system component
levels in tumour tissue extracts and OS (Additional file
1: Tables S2 and S3). On the contrary, in the analysis of
DSS we found an association between high uPAR anti-
gen levels and an increased risk of cancer-related deathwith a trend towards significance for patients with organ-
confined tumours in either univariate or multivariate Cox
regression analysis with HRs of 3.15 (95% CI 0.97-10.2, P =
0.057) and 3.09 (95% CI 0.88-10.8, P = 0.077), respectively
(Additional file 1: Tables S2 and S3).
Analysis of combined uPA system component levels in
tumour tissues for survival of ccRCC patients
In the next step, we assessed whether the pair-wise com-
bination of uPA, uPAR and PAI-1 antigen levels could
improve the prognostic power of either single marker.
For this, the ccRCC patient cohort was divided into two
groups: a group with low levels of each of both markers
analysed, and another with high levels of one or both
markers. In the whole patient cohort, the marker combi-
nations of high antigen levels of either uPA and/or
uPAR, uPA and/or PAI-1 or uPAR and/or PAI-1 were
found to be significantly associated with shorter DSS in
univariate Cox’s regression analyses (Additional file 1:
Table S1). Particularly, the co-detection of high antigen
levels of uPA and/or uPAR added significant prognostic
information for DSS in ccRCC patients with a HR of
12.6 (95% CI 1.69-94.1; P = 0.013). Moreover, in multi-
variate analyses using the base model mentioned
above (comprising gender, age, tumour stage and
tumour grade), we found that combined high antigen
levels of uPA and/or uPAR resulted in an even better
prediction of DSS represented by a HR of 14.5 (95%
CI 1.88-111.1, P = 0.010), which was independent of
other factors (Table 4). The combined antigen levels
of high uPA and/or PAI-1 (HR = 4.24, 95% CI 1.21-
14.9, P = 0.024) did also provide additional prognostic
information (Table 4).
In addition, in the subgroup of patients with organ-
confined disease, those with low antigen levels of both
uPA and uPAR were characterised by a longer DSS than
patients with tumours with high levels of one or both
markers (Table 5). Patients with pT1+2 tumours with
high levels of uPA and/or uPAR showed a significantly
increased risk of cancer-related death (HR = 9.83; 95%
CI 1.21-79.6, P = 0.032) compared to pT1+2 patients
who had low uPA and uPAR levels (Table 5). Thus, a
pronounced additive effect on prognosis of pT1+2
ccRCC patients, i.e. patients with an assumed lower risk
of cancer-related death, was identified when combining
uPA and uPAR antigen levels in tumour tissue. The
other combinations of high uPA and/or PAI-1 or uPAR
and/or PAI-1 did not provide any additional prognostic
information for ccRCC patients with organ-confined
disease (Table 5).
For overall survival, none of the marker combinations
represented a significant predictor in univariate or
multivariate Cox’s regression analyses neither in the
whole cohort nor in the subgroup of ccRCC patients
Table 3 Associations of uPA system components in tumour tissue specimens with disease-specific survival (DSS) and
overall survival (OS) of patients with ccRCC (n = 112) assessed by multivariate Cox’s regression analysis
Factor No. cases Disease-specific survival HR (95% CI)a P Overall survival HR (95% CI)a P
Gender
male 65 1 1
female 47 0.93 (0.38-2.28) 0.880 1.65 (0.79-3.45) 0.179
Age (years)
≤64 57 1 1
>64 55 2.31 (0.89-5.99) 0.085 2.52 (1.26-5.07) 0.009
Tumour stage
pT1+2 87 1 1
pT3+4 25 1.85 (0.73-4.69) 0.192 1.17 (0.56-2.44) 0.670
Tumour grade
G1+2 68 1 1
G3+4 44 2.08 (0.83-5.19) 0.118 1.61 (0.82-3.14) 0.165
uPAb
low 53 1 1
high 59 2.86 (1.07-7.67) 0.037 1.28 (0.66-2.51) 0.467
uPARb
low 55 1 1
high 57 4.70 (1.51-14.6) 0.008 1.60 (0.80-3.23) 0.185
PAI-1b
low 56 1 1
high 56 2.59 (0.95-7.08) 0.064 1.71 (0.85-3.46) 0.135
aHR: hazard ratio; 95% CI: 95% confidence interval of multivariate Cox’s regression analysis; uPA system factors were separately added to the base model
consisting of gender, age, tumour stage and tumour grade.
bDichotomised into groups with high and low levels of uPA system factors by the median values.
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and S2, Tables 4 and 5).
Discussion
In the present study, we aimed at analysing the protein
levels of uPA system components in tissue extractsTable 4 Associations of combinations of uPA system componen
(DSS) and overall survival (OS) of patients with ccRCC (n = 112)
Factor No. cases Disease-specific survival HR
uPA/uPARb
uPA and uPAR low 41 1
uPA and/or uPAR high 71 14.5 (1.88-111.1)
uPA/PAI-1b
uPA and PAI-1 low 43 1
uPA and/or PAI-1 high 69 4.24 (1.21-14.9)
uPAR/PAI-1b
uPAR and PAI-1 low 40 1
uPAR and/or PAI-1 high 72 3.47 (0.98-12.2)
aHR: hazard ratio; 95% CI: 95% confidence interval of multivariate Cox’s regression a
model consisting of gender, age, tumour stage and tumour grade.
bDichotomised into groups with high and low levels of uPA system factors by the mfrom matched malignant and corresponding non-
malignant tissue kidney specimens in a cohort of 112
ccRCC patients without distant metastasis and at
assessing their potential associations with clinicopath-
ological parameters and the prognostic relevance in
ccRCC patients.ts in tumour tissue specimens with disease-specific survival
assessed by multivariate Cox’s regression analysis
(95% CI)a P Overall survival HR (95% CI)a P
1
0.010 1.34 (0.64-2.82) 0.438
1
0.024 1.63 (0.78-3.40) 0.196
1
0.053 1.56 (0.73-3.36) 0.255
nalysis; combinations of uPA system factors were separately added to the base
edian values.
Table 5 Association of the combination of uPA system component levels in tumour tissue specimens with
disease-specific survival (DSS) and overall survival (OS) in the subgroup of ccRCC patients with organ-confined
tumours (tumour stage pT1+2, n = 87) assessed by multivariate Cox’s regression analysis
Factor No. cases Disease-specific survival HR (95% CI) a P Overall survival HR (95% CI) a P
uPA/uPARb
uPA and uPAR low 35 1 1
uPA and/or uPAR high 52 9.83 (1.21-79.6) 0.032 1.03 (0.45-2.37) 0.942
uPA/PAI-1b
uPA and PAI-1 low 37 1 1
uPA and/or PAI-1 high 50 3.23 (0.79-13.1) 0.101 1.30 (0.56-3.02) 0.541
uPAR/PAI-1b
uPAR and PAI-1 low 35 1 1
uPAR and/or PAI-1 high 52 2.68 (0.67-10.8) 0.164 1.39 (0.58-3.29) 0.460
aHR: hazard ratio; 95% CI: 95% confidence interval of multivariate Cox’s regression analysis; combinations of uPA system factors were separately added to the base
model consisting of gender, age and tumour grade.
bDichotomised into groups with high and low levels of uPA system factors by the medians.
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lyte/mg of total protein) determined in detergent ex-
tracts of corresponding malignant and non-malignant
kidney tissues in our study were comparable to those re-
ported in previous studies applying the same commercially
available ELISA kits (IMUBIND from Sekisui/American
Diagnostica) or using in-house ELISA formats (see Table 6).
Conversely, in cytosolic tumour tissue extracts, consider-
ably lower uPA concentrations were measured, whereas the
PAI-1 antigen levels were comparable [22].
The concentration of uPA system components has
been reported to differ between malignant and non-
malignant renal tissues (see Table 6). All mentioned
studies including our present analyses demonstrated sig-
nificantly higher protein levels of PAI-1 in RCC tissues
compared to normal renal tissues (see Table 6). With re-
gard to uPA and uPAR, the observations in the different
studies vary. While Swiercz et al. [23] observed signifi-
cantly elevated uPA levels in the tumour specimens,
others found no significant differences between malig-
nant and non-malignant renal tissues [22,24,25,32]. In
contrast, in our study uPA protein levels were signifi-
cantly decreased in ccRCC tissues compared to the cor-
responding non-malignant specimens. The reasons for
these discrepancies between the different reports remain
unclear so far. Hofmann et al. [24,25], who used the
same strategy and analysed a similar number of patients
as we did, measured comparable uPA levels in the corre-
sponding renal tissue specimens, whereas Span et al.
[32] obtained a similar trend of uPA levels in malignant
and non-malignant renal tissues as in our study, which
did not reach statistical significance (P = 0.081).
For uPAR, we found no differences between corre-
sponding malignant and non-malignant tissue of ccRCC
patients. In contrast, significantly higher uPAR antigen
concentrations have been observed in RCC tissuescompared to benign renal tissue in previous reports
[23,24]. These discrepancies might originate from differ-
ences in the numbers of analysed tissue samples. While
112 pairs of corresponding malignant and non-malignant
renal tissues were used in our study, Hofmann et al. [24]
assessed uPAR levels only in 49 matched tissue pairs and
Swiercz et al. [23] compared 52 RCC tissues with 28 nor-
mal tissues of different origin (Table 6). Furthermore, levels
of uPA system components might differ between the RCC
subtypes. We analysed only patients with ccRCC, but no in-
formation on the subtype is given in the mentioned reports
[23,24]. Interestingly, Chautard et al. [22] observed clear
differences in uPA and PAI-1 levels between tissue speci-
mens from ccRCC (n = 85), papillary RCC (n = 11) and sar-
comatoid RCC (n = 4) indicating that the RCC subtype is
of importance and the use of mixed patient cohorts ham-
pers the drawing of definite conclusions (Table 6).
In the tumour tissues, we found significant, moder-
ately high correlations between the antigen levels of all
three components of the uPA system (rs values between
0.51 and 0.65). Similar positive correlations have in fact
been previously reported between uPA, uPAR, and PAI-
1 in tumour tissue extracts of RCC patients [24,25].
Strikingly, significant correlations between antigen levels
of these factors in tumour tissues have been also ob-
served in various other types of cancer [33-35]. The reg-
ulated expression of uPA system components in a
concerted manner in tumour growth and metastasis may
be attributed to the various interactions within the uPA
system [11,16]. In contrast, we found only low correlations
between uPA system components in non-malignant renal
tissues, which is in line with observations on tumour-free
samples of other tumour entities [32,36]. This may be
caused by various mechanisms of expression regulation
and functional interplay between these factors under
physiological conditions [11].
Table 6 Overview of median protein levels of uPA, uPAR and PAI-1 determined by different ELISA formats in malignant
and non-malignant renal tissue specimens
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105 for uPA, 49 for uPAR,
96 for PAI-1











n = 28: 3 RCC-free kidneys,
18 normal tissues from RCC-kidneys,














ELISA for uPAR American Diagnostica American Diagnostica n.d. n.d. American
Diagnostica











in Tu 0.29 n.p. 0.091 (0.043 in ccRCC) 0.50 0.41
in Tf 0.286 n.p. 0.078 0.71 0.61
Difference
between Tu vs Tf
n.s. (Tu = Tf) P = 0.01 (Tu > Tf) n.s. (Tu > Tf) n.s. (Tu < Tf) P = 0.001 (Tu < Tf)
uPAR
in Tu 0.78 n.p. n.d. n.d. 0.51
in Tf 0.30 n.p. n.d. n.d. 0.52
Difference
between Tu vs Tf
P = 0.018 (Tu > Tf) P = 0.007 (Tu > Tf) n.d. n.d. n.s. (Tu = Tf)
PAI-1
in Tu 11.08 n.p. 40.8 (38.7 in ccRCC) 7.26 10.3
in Tf 4.221 n.p. 5.8 0.92 3.13
Difference
between Tu vs Tf
P = 0.02 (Tu > Tf) P = 0.001 (Tu > Tf) P < 0.001 (Tu > Tf) P < 0.001 (Tu > Tf) P = 0.001 (Tu > Tf)
n.d.: not determined; n.p.: not provided; n.s.: not significant; Tf: non-malignant tissues; Tu: malignant tissues.
aOnly P-values were given for differences between malignant and non-malignant tissue samples, which are presented in box plots.
bResults are converted from pg/mg to ng/mg.
cMean levels are shown since medians were not provided.
Levels of uPA, uPAR and PAI-1 were normalised to total protein concentration and expressed as ng analyte per mg of total protein.
Fuessel et al. BMC Cancer 2014, 14:974 Page 9 of 12
http://www.biomedcentral.com/1471-2407/14/974Only few studies have analysed the protein levels of
uPA system components in RCC specimens with regard
to their dependence on clinicopathological parameters
and to their impact on prognosis of RCC patients. In the
present study, we observed significantly elevated antigen
levels of all three uPA system components in tissue
specimens from non-organ confined tumours compared
to organ-confined tumours. Furthermore, significantly
increased levels of uPAR and PAI-1 could be detected in
high grade tumours in comparison to low grade tu-
mours. In accordance to our results, Swiercz et al. [23]
reported elevated protein levels of uPA, uPAR and PAI-1
in tissue extracts from high grade RCC. Chautard et al.
[22] also detected a gradual increase of uPA and PAI-1
protein levels in RCC extracts with higher tumour grade
and stage, whereas only the relation between PAI-1 and
grade reached statistical significance. A positive relationbetween the immunoreactive scores of uPA, uPAR or
PAI-1 and tumour grade, tumour stage or metastasis
was described by Ohba et al. [19] who performed immu-
nohistochemical analyses on 106 RCC patients. Two
other immunohistochemical studies on ccRCC patients
also described significant positive associations of PAI-1
staining with tumour grade as well as with tumour stage
[20,21]. On the contrary, the studies by Hofmann et al.
[24,25] did not reveal any association between protein
levels of uPA, uPAR or PAI-1 in tissue extracts and
tumour grade or stage.
Moreover, data on the influence of the protein expres-
sion of uPA system members on survival of RCC pa-
tients are partially contradictory depending on the
detection method used [19,22,24]. In the present study,
all three uPA system components were significant pre-
dictors for DSS in univariate Cox’s regression analyses
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prognostic factors for DSS in multivariate analyses. The
combination of both factors further improved the pre-
diction of DSS in multivariate analysis considerably
(Table 4; HR=14.5, 95% CI 1.88-111.1, P=0.010). These
results are in line with the data of the immunohisto-
chemical analyses reported by Ohba et al. [19] who re-
vealed that increased protein levels of all three factors
were associated with poor DSS. Nevertheless, only PAI-1
emerged as independent predictive factor in their multi-
variate Cox’s regression analyses [19].
In the report of Hofmann et al. [24] who considered –
in contrast to our study – the time from surgery to
tumour progression, all three factors appeared also as
strong predictors for a higher risk of relapse. In contrast,
uPA and PAI-1 protein levels in cytosolic tissue extracts
were not independently predictive for metastasis as re-
ported by Chautard et al. [22] but elevated uPA levels
were significantly associated with a shorter disease-free
survival (DFS) in univariate Cox’s regression analyses.
Similarly, Choi et al. [20] described a significant relation
between high PAI-1 immunoexpression and a shorter
DFS, albeit this could not be confirmed in multivariate
Cox’s regression analyses. In comparison to this, the im-
munohistochemical study by Zubac et al. [21] revealed
PAI-1 as a significant prognostic factor for disease-specific
survival both in univariate and multivariate Cox’s regres-
sion analyses. Taken together, previous studies demon-
strated a prognostic potential of uPA and uPAR, and most
obviously, for PAI-1 protein levels in RCC tissues. In con-
trast, high levels of uPA and uPAR in ccRCC extracts were
shown to be associated with a significantly shorter DSS of
ccRCC patients in our study. The differing study results
may originate from variances in the applied methods and
used cut-off points as well as in the patient cohorts with
regard to the inclusion of patients with diverse RCC sub-
types, metastatic status and follow-up endpoints.
Finally, we evaluated the predictive value of the three
uPA system components for patients with an organ-
confined tumour who are usually expected to have a
favourable outcome but still can progress after tumour
nephrectomy given the highly aggressive nature of
ccRCC. Surprisingly, the DSS of those patients could be
further stratified on the basis of combined tissue protein
levels of uPA and uPAR (Additional file 1: Table S2,
Table 5). The HR of 9.83 (P = 0.032) obtained for pa-
tients with high levels of uPA and/or uPAR in multivari-
ate analysis in the pT1+2 subgroup further emphasises
the potential prognostic utility of uPA and uPAR protein
expression for patients with ccRCC. Based on these find-
ings, it might be also of interest to specifically determine
the concentration of the uPA/uPAR complex with hybrid
sandwich-type ELISAs and its relation to prognosis of
the patients [37].Moreover, Zubac et al. [21] could show that PAI-1
immunoexpression turned out to be a highly significant
predictor for metastatic relapse in patients with organ-
confined RCC. These results suggests that the deter-
mination of protein levels of uPA system components in
patients with pT1 and pT2 tumours may provide add-
itional prognostic information that may allow for individ-
ual, risk-adapted therapy decisions. Patients at higher risk
of relapse could be treated by targeted agents in an adju-
vant setting as currently evaluated in a number of ongoing
prospective clinical trials [6]. For primary breast cancer,
the determination of uPA and PAI-1 antigen levels in
tumour tissue extracts has already entered clinical practice
for risk stratification and individual therapy decisions in
patients with lymph node-negative disease [16,38]. This
approach might be also imaginable for ccRCC patients
without distant metastasis, particularly for those with
organ-confined tumours, but needs further elucidation in
prospective clinical trials.
Conclusions
The present study, to our knowledge, is the first report on
the parallel assessment of protein levels of uPA, uPAR and
PAI-1 in detergent tissue extracts of renal tissue speci-
mens in a consistent cohort of 112 patients with ccRCC
and without clinically detectable distant metastasis at the
time of diagnosis. Comparable previous studies were per-
formed using tissue samples originating from different
RCC subtypes and follow-up endpoints, inconsistent co-
hort sizes, optimised cut-off points or non-detergent tissue
extracts or analysed not all three factors in parallel (see
Table 6). Our study tried to overcome these shortcomings,
and revealed a considerable, independent prognostic po-
tential of uPA and uPAR protein levels in tumour tissue
extracts for DSS. Best prediction of DSS might be achieved
by the combination of elevated protein levels of uPA and/
or uPAR compared to low levels of both factors. Particu-
larly, this holds true for the subgroup of ccRCC patients
with organ-confined tumours, whose outcome in general
is assumed to be favourable but can be further stratified
on the basis of the protein levels of uPA and uPAR.
Despite the strengths of our retrospective study on 112
ccRCC patients, future prospective validation studies have
to elucidate independently the prognostic value of the
uPA system components for ccRCC patients.
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